98%
921
2 minutes
20
This article discusses the article written by Tan . Transarterial chemoembolization (TACE) is one of the main treatment methods for advanced hepatocellular carcinoma (HCC). There are other vascular interventional therapies, including drug-eluting bead TACE, transarterial radioembolization, and hepatic arterial infusion chemotherapy. TACE combined with anti-angiogenesis therapy may improve tumor control and prolong progression free survival. The combination therapy of TACE and immunotherapy may improve the clinical efficacy of HCC. In future research, more basic and clinical studies are needed to explore the immunogenic intervention therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650251 | PMC |
http://dx.doi.org/10.4240/wjgs.v16.i12.3903 | DOI Listing |
Cardiovasc Intervent Radiol
September 2025
The Department of Radiology, Wakayama Medical University, Wakayama, Japan.
Purpose: Recent advancements in medical technologies have made trans-arterial treatment of breast cancer feasible. Consequently, understanding the vascular anatomies of breast cancers and axillary lymph node metastases has become indispensable for sophisticated treatments. The aim of this study was to determine the vascular anatomy of the breast, which is crucial for trans-arterial chemoembolization in patients with breast cancer.
View Article and Find Full Text PDFCardiovasc Intervent Radiol
September 2025
Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea.
Purpose: To evaluate the preclinical efficacy and safety of transarterial chemoembolization (TACE) using doxorubicin-loaded biocompatible cellulose nanoparticles in a rabbit VX2 liver tumor model.
Materials And Methods: Following institutional animal care committee approval, 23 rabbits with VX2 liver tumors were randomized into three groups: Group A (n = 9) received doxorubicin-loaded cellulose nanoparticles with ethiodized oil; Group B (n = 9) received doxorubicin with ethiodized oil; and Group C (n = 5) served as untreated controls. Tumor size was monitored via ultrasound for 4 weeks, and serum liver enzymes (aspartate transaminase and alanine transaminase) were measured on days 1, 3, and 7 to assess hepatotoxicity.
Medicine (Baltimore)
September 2025
Department of Integrated Traditional Chinese and Western Medicine, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Background: This network meta-analysis (NMA) aims to compare the relative efficacy of oral Chinese patent medicine combined with transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC).
Methods: Databases, including China National Knowledge Infrastructure, Wanfang, Weipu, PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL), were accessed from inception to the present to collect randomized controlled trials of different oral Chinese patent medicines (OCPMs). Objective response rate, 1-year survival rate, lymphocytes, nausea and vomiting were used as efficacy or tolerability outcomes.
Int J Surg
September 2025
The Affiliated Nanhai Hospital of Traditional Chinese Medicine of Jinan University, Foshan, China.
J Hepatocell Carcinoma
August 2025
Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Purpose: Transarterial chemoembolization (TACE) may cause gut dysbiosis by increasing portal vein pressure. However, its association with clinical outcomes remains unknown. We hypothesized that gut microbiota composition and diversity are associated with treatment response and prognosis in patients with hepatocellular carcinoma (HCC) undergoing TACE.
View Article and Find Full Text PDF